Pulmatrix Receives European Patent for its Inhaled Drug Delivery Technology

LEXINGTON, Mass., March 21, 2017 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announced that it has received a key patent from the European Union.

"This new patent shows our continued ability to obtain patents that protect our unique iSPERSE inhaled drug technology—and that also reflect the advances we are making in drug delivery," said Robert W. Clarke, Ph.D., Chief Executive Officer for Pulmatrix. "It gives us a strong intellectual property protection position in Europe as we move forward with our drug candidates for COPD, fungal infections, and other diseases."

The new EU patent (EP 2410981 B1) follows on similar patents that Pulmatrix has been granted in the United States and Japan. The most important of those patents is US 9,433,576, which gives broad protection to Pulmatrix's innovative drug delivery technology—and to its use to treat a wide variety of diseases.

These patents explain that delivering drugs directly to the lungs offers numerous advantages. But the full potential can't be realized unless most of the drug actually gets to the lungs, rather than being stuck in the throat or mouth, causing side effects. Pulmatrix's technology uses dry powders that 'fly' easily into the lungs, making the delivery much more efficient. In addition, the technology can deliver much larger doses of drugs—and many more different types of drugs—than existing methods can.

"This new patent means that we are now protected from competitors copying our advances in Europe, as well as in the United States," added Dr. Clarke.

About Pulmatrix       
Pulmatrix is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease using its patented iSPERSE™ technology. The Company's proprietary product pipeline is focused on advancing treatments for lung diseases, including  opportunities in major pulmonary diseases through collaborations, like PUR0200, a branded generic in clinical development for chronic obstructive pulmonary disease (COPD) and PUR1900, an inhaled antifungal that could benefit severe asthmatics and patients with rare disease like cystic fibrosis.  Pulmatrix's product candidates are based on iSPERSE™, its proprietary dry powder delivery platform, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes.

FORWARD-LOOKING STATEMENTS
Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements concerning the amount and use of proceeds the Company expects to receive from the sale of the shares of common stock in the registered direct offering, the closing of the transaction described in this press release, which is subject to customary conditions, and other statements that are not statements of historical fact, and may be identified by words such as "anticipates," "assumes," "believes," "can," "could," "estimates," "expects," "forecasts," "guides," "intends," "is confident that", "may," "plans," "seeks," "projects," "targets," and "would," and their opposites and similar expressions are intended to identify forward-looking statements. The Company cautions that such statements involve risks and uncertainties that may materially affect the Company's results of operations. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, market and other conditions, the satisfaction of customary closing conditions related to the registered direct offering of common stock, the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of therapeutic candidates; the ability to obtain appropriate or necessary governmental approvals to market potential products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; the Company's ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; and the ability to secure and enforce legal rights related to the Company's products, including patent protection. A discussion of these and other factors, including risks and uncertainties with respect to the Company, is set forth in the Company's filings with the Securities and Exchange Commission, including its annual report on Form 10-K filed with the Securities and Exchange Commission on March 10, 2017, as may be supplemented or amended by the Company's Quarterly Reports on Form 10-Q. The Company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Investor Contact                                             
Robert Clarke, CEO                                                      
(781) 357-2333                                                                       
rclarke@pulmatrix.com                                

William Duke, CFO
(781) 357-2333 
wduke@pulmatrix.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/pulmatrix-receives-european-patent-for-its-inhaled-drug-delivery-technology-300426322.html

SOURCE Pulmatrix, Inc.